AIOVA is an emerging biotech company focusing on the development of innovative DNA vaccines to fight against emergent or re-emergent infectious diseases such as HIV (causing AIDS), Influenza (Flu) and right now against the SARS-CoV-2 and its variants (COVID). Such infectious diseases are threatening the human and animal lives by causing regularly global and deadly pandemics. Numbers of these viral pandemics are expected to increase because of massive urbanization and environmental degradation resulting from climate change.
AIOVA develops the next generation of DNA vaccines to promptly, effectively, and sustainably tackle these emergent and re-emergent infectious diseases. AIOVA owns a patented eDNA platform with intrinsic and unique properties conferring augmented immunity and protection compared to other vaccine platforms (including other DNA vaccines). Injecting the DNA vaccine in the host induces a safe, protective, strong and long-lasting immunity (several years) as well as a protection against the original virus and its variants (so-called pan or universal vaccines). Moreover, DNA vaccines are easy and fast to design and manufacture, with reduced costs, ensuring high profitability.
AIOVA’s business model is based both on the licensing of rights on products resulting from its R&D, and on strategic partnerships with pharmaceutical industrials.
Members directory
AIOVA is an emerging biotech company focusing on the development of innovative DNA vaccines to fight against emergent or re-emergent infectious diseases such as HIV (causing AIDS), Influenza (Flu) and right now against the SARS-CoV-2 and its variants (COVID). Such infectious diseases are threatening the human and animal lives by causing regularly global and deadly pandemics. Numbers of these viral pandemics are expected to increase because of massive urbanization and environmental degradation resulting from climate change.
AIOVA develops the next generation of DNA vaccines to promptly, effectively, and sustainably tackle these emergent and re-emergent infectious diseases. AIOVA owns a patented eDNA platform with intrinsic and unique properties conferring augmented immunity and protection compared to other vaccine platforms (including other DNA vaccines). Injecting the DNA vaccine in the host induces a safe, protective, strong and long-lasting immunity (several years) as well as a protection against the original virus and its variants (so-called pan or universal vaccines). Moreover, DNA vaccines are easy and fast to design and manufacture, with reduced costs, ensuring high profitability.
AIOVA’s business model is based both on the licensing of rights on products resulting from its R&D, and on strategic partnerships with pharmaceutical industrials.
AIOVA
Université Grenoble-Alpes.
Bât. NanoBio, 570 rue de la Chimie.
38400 Saint Martin d’Hères
Date of creation : 2019
Number of employees : 2
https://www.linksium.fr/projet/vaccyvet/
CEO
RONFORT Corinne
+33 (0)6 98 78 32 38
corinne.ronfort@inrae.fr